

# **ONS/ONCC Chemotherapy Immunotherapy CAQ Renewal Practice Test Sample Study Guide**



**EVERYTHING you need from our exam experts!**

**Featuring practice questions, answers, and explanations  
for each question.**

**This study guide is a SAMPLE. Visit  
<https://onsonccchemorenewal.examzify.com> to  
get the full version available exclusively to  
Examzify Plus pass holders .**

**Copyright © 2025 by Examzify - A Kaluba Technologies Inc. product.**

**ALL RIGHTS RESERVED.**

**No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.**

**Notice: Examzify makes every reasonable effort to obtain from reliable sources accurate, complete, and timely information about this product.**

**SAMPLE**

## **Questions**

- 1. How should a nurse respond to a patient experiencing severe nausea after chemotherapy?**
  - A. Assess the severity and provide antiemetic medication**
  - B. Offer dietary changes and alternative therapies**
  - C. Suspend chemotherapy treatment immediately**
  - D. Encourage the patient to manage symptoms on their own**
- 2. In monitoring LVEF for patients receiving pertuzumab, how often should it be checked?**
  - A. Every 3 weeks**
  - B. Every 6 weeks**
  - C. Every month**
  - D. Every 2 months**
- 3. Which home care step can help prevent worsening of early mucositis?**
  - A. Limiting oral intake**
  - B. Ensuring proper oral care**
  - C. Using ice chips frequently**
  - D. Avoiding all medications**
- 4. How does the dosing of chemotherapy agents typically depend on the patient's characteristics?**
  - A. It is generally based on the patient's age**
  - B. It often depends on the patient's body surface area (BSA)**
  - C. It is standard for all patients regardless of characteristics**
  - D. It is based solely on the type of cancer**
- 5. What is the significance of tumor markers in oncology?**
  - A. They help in diagnosing, monitoring treatment response, and detecting recurrence**
  - B. They provide information solely about treatment options**
  - C. They indicate the type of cancer exclusively**
  - D. They are used for imaging purposes only**

- 6. For calculating ANC, what was the total percentage of bands and polys provided?**
- A. 20%**
  - B. 22%**
  - C. 26%**
  - D. 30%**
- 7. Why is it critical to assess a patient's performance status before chemotherapy?**
- A. To determine their ability to tolerate treatment and predict outcomes**
  - B. To identify potential side effects of the treatment**
  - C. To establish the need for nutritional support**
  - D. To plan for follow-up appointments**
- 8. What symptom may signal a patient is experiencing myelosuppression during chemotherapy?**
- A. Weight loss**
  - B. Increased energy**
  - C. Frequent infections**
  - D. Improved mood**
- 9. What is a common reason to perform regular blood tests in cancer patients?**
- A. To monitor for secondary infections**
  - B. To determine appetite changes**
  - C. To evaluate treatment efficacy and manage toxicity**
  - D. To assess physical strength**
- 10. What role does hydration play in chemotherapy treatment?**
- A. Prevents hair loss**
  - B. Aids in drug elimination and reduces side effects**
  - C. Improves the taste of food**
  - D. Increases appetite**

## **Answers**

SAMPLE

1. A
2. B
3. B
4. B
5. A
6. C
7. A
8. C
9. C
10. B

SAMPLE

## **Explanations**

SAMPLE



**1. How should a nurse respond to a patient experiencing severe nausea after chemotherapy?**

- A. Assess the severity and provide antiemetic medication**
- B. Offer dietary changes and alternative therapies**
- C. Suspend chemotherapy treatment immediately**
- D. Encourage the patient to manage symptoms on their own**

The appropriate response to a patient experiencing severe nausea after chemotherapy is to assess the severity of the symptoms and provide antiemetic medication. This approach is crucial because severe nausea can significantly impact a patient's quality of life and their ability to continue with treatment. By assessing the severity, the nurse can determine if the nausea is a mild issue that could be managed with over-the-counter remedies or if it requires a stronger prescription antiemetic. Administering antiemetic medications promptly is essential for managing chemotherapy-induced nausea and vomiting (CINV). These medications can help prevent nausea from becoming more severe and can allow the patient to better tolerate their treatment and maintain adequate nutrition and hydration. Effective management of these side effects can also improve the patient's overall sense of well-being and willingness to continue their treatment plan. The other options, while they may have some validity in certain contexts, do not address the immediate needs of the patient experiencing severe nausea. Offering dietary changes and alternative therapies may be beneficial in a supportive care context but should not replace the need for medical management of severe symptoms. Suspending chemotherapy treatment immediately is not a standard response, as it may inadvertently harm the patient's treatment plan. Encouraging the patient to manage symptoms on their own is not appropriate in the case of

**2. In monitoring LVEF for patients receiving pertuzumab, how often should it be checked?**

- A. Every 3 weeks**
- B. Every 6 weeks**
- C. Every month**
- D. Every 2 months**

Monitoring left ventricular ejection fraction (LVEF) is critical for patients receiving pertuzumab, especially because this medication is often used in combination therapies that can exacerbate cardiac toxicity. The recommended frequency for checking LVEF is every 6 weeks. This timeline allows clinicians to effectively monitor any potential decline in cardiac function that may arise during treatment. Checking the LVEF at this interval strikes a balance between ensuring patient safety and managing the logistical aspects of frequent imaging or monitoring, as this frequency is aligned with the pharmacokinetics and potential side effects observed in clinical practice. Regular monitoring at this interval provides timely information that can guide further therapy decisions and ensure that any cardiac side effects are identified early, enabling prompt intervention if necessary.

**3. Which home care step can help prevent worsening of early mucositis?**

- A. Limiting oral intake**
- B. Ensuring proper oral care**
- C. Using ice chips frequently**
- D. Avoiding all medications**

Ensuring proper oral care is essential in preventing the worsening of early mucositis. Mucositis is an inflammation of the mucous membranes in the mouth, which can occur as a side effect of treatments like chemotherapy or radiation. Proper oral hygiene helps to maintain the integrity of the oral mucosa, reduce the risk of infection, and alleviate symptoms associated with mucositis. Regular brushing with a soft-bristled toothbrush, using mouth rinses to keep the mouth clean, and staying hydrated can significantly minimize irritation and discomfort. This proactive measure not only helps to prevent mucositis from developing further but can also promote healing if early symptoms are already present. The other options, while they may seem helpful, do not have the same direct impact on managing oral health and mucositis effectively.

**4. How does the dosing of chemotherapy agents typically depend on the patient's characteristics?**

- A. It is generally based on the patient's age**
- B. It often depends on the patient's body surface area (BSA)**
- C. It is standard for all patients regardless of characteristics**
- D. It is based solely on the type of cancer**

The dosing of chemotherapy agents is typically based on a patient's body surface area (BSA) due to its ability to more accurately reflect the volume of distribution and clearance of chemotherapy drugs in relation to a patient's size. BSA provides a better understanding of the metabolic capacity of an individual's body, which is crucial because chemotherapy agents can have varying effects depending on how they metabolize within different sized individuals. Dosing by BSA allows for a more personalized approach to treatment, accommodating different physiological responses to drugs. This method helps to optimize efficacy while minimizing toxicity, as chemotherapy is notorious for its adverse effects. In contrast, using age or standard doses across all patients does not take into account the significant variations in body composition and metabolism that can occur with different patients. Relying solely on the type of cancer to determine dosing overlooks the individual characteristics that influence treatment response and side effects. Thus, BSA remains the most established and effective metric for dosing chemotherapy agents.

**5. What is the significance of tumor markers in oncology?**

- A. They help in diagnosing, monitoring treatment response, and detecting recurrence**
- B. They provide information solely about treatment options**
- C. They indicate the type of cancer exclusively**
- D. They are used for imaging purposes only**

The significance of tumor markers in oncology is encapsulated in their multifaceted roles, which include aiding in diagnosis, monitoring treatment response, and detecting recurrence. Tumor markers are substances produced by cancer cells or by the body in response to cancer, and their presence in the body can provide valuable information. In the diagnosis phase, certain tumor markers can help confirm the presence of specific types of cancer. For instance, PSA (Prostate-Specific Antigen) is used in diagnosing prostate cancer. During treatment, monitoring levels of tumor markers can indicate how the body is responding to therapies, whether the treatment is effective, or if modifications to the treatment plan are necessary. Finally, after initial treatment, these markers can be helpful in surveillance for the recurrence of cancer, as rising levels may suggest that cancer has returned. The other options do not satisfactorily capture the comprehensive role of tumor markers. The second option narrows the role of tumor markers to treatment options, neglecting their critical function in diagnostics and follow-up. The third option incorrectly suggests that tumor markers exclusively indicate the type of cancer, overlooking their role in disease monitoring. The fourth option restricts their application to imaging, which is not accurate; tumor markers do not serve as imaging tools but rather as biochemical substances

**6. For calculating ANC, what was the total percentage of bands and polys provided?**

- A. 20%**
- B. 22%**
- C. 26%**
- D. 30%**

The total percentage of bands and polys, which are types of neutrophils, is critical for calculating the Absolute Neutrophil Count (ANC). To determine the ANC, one must consider both the mature neutrophils (polys) and the immature neutrophils (bands) because both contribute to the body's ability to fight infections. The correct answer reflects a thoughtful summation of the proportions of bands and polys presented in the original data. It is essential to accurately sum these values because the resulting percentage directly affects patient care decisions, such as the management of infections or chemotherapy administration. In a clinical context, if bands and polys together constitute 26% of the total white blood cell count, knowing this figure is vital for healthcare providers to assess a patient's immune status effectively. The ANC is calculated by multiplying the total white blood cell count by the percentage of neutrophils (bands plus polys). This relationship highlights the importance of understanding and calculating these values accurately in patient management. Other percentages would not provide the correct reflection of the combined leukocyte population critical for evaluating neutrophil levels in patients, which might lead to misinterpretation of the patient's immunocompromised state. Thus, 26% is the appropriate total for bands and polys

**7. Why is it critical to assess a patient's performance status before chemotherapy?**

- A. To determine their ability to tolerate treatment and predict outcomes**
- B. To identify potential side effects of the treatment**
- C. To establish the need for nutritional support**
- D. To plan for follow-up appointments**

Assessing a patient's performance status before chemotherapy is crucial because it provides vital information about the patient's overall health and functional capabilities. This assessment helps healthcare providers determine the patient's ability to tolerate the treatment regimen being considered. A good performance status indicates that the patient is likely to handle chemotherapy well, which correlates with better outcomes. Conversely, a poor performance status might suggest that the patient is at higher risk for complications, adverse effects, or may not benefit from aggressive treatment. This evaluation helps guide treatment decisions, such as whether to proceed with chemotherapy, adjust the doses, or consider alternative therapies. While the other options touch on important aspects of patient care, they do not capture the primary reason for assessing performance status prior to chemotherapy as comprehensively as the correct choice. Identifying potential side effects, establishing nutritional support, and planning for follow-up appointments are significant, but they stem from a foundational understanding of how well the patient can withstand the rigors of chemotherapy.

**8. What symptom may signal a patient is experiencing myelosuppression during chemotherapy?**

- A. Weight loss**
- B. Increased energy**
- C. Frequent infections**
- D. Improved mood**

Myelosuppression is a condition where bone marrow activity is decreased, leading to a reduction in the production of blood cells. Symptoms of myelosuppression are closely related to the decreased levels of white blood cells (leukocytes), red blood cells (erythrocytes), and platelets (thrombocytes) resulting from chemotherapy. Frequent infections are a key symptom indicating myelosuppression because they are primarily a result of a low white blood cell count, specifically neutropenia, which makes the immune system less capable of fighting off infections. Patients undergoing chemotherapy often experience this as their immune systems become compromised due to the suppression of the bone marrow. In contrast, weight loss, increased energy, and improved mood are typically not associated with myelosuppression. Weight loss might occur due to other factors related to cancer or treatment but is not a direct indicator of diminished blood cell production. Increased energy and improved mood are also counterintuitive to the effects of chemotherapy, which generally leads to fatigue and malaise. Therefore, frequent infections stand out as a significant sign that warrants further evaluation for myelosuppression during chemotherapy.

**9. What is a common reason to perform regular blood tests in cancer patients?**

- A. To monitor for secondary infections**
- B. To determine appetite changes**
- C. To evaluate treatment efficacy and manage toxicity**
- D. To assess physical strength**

Performing regular blood tests in cancer patients is essential primarily to evaluate treatment efficacy and manage toxicity. Blood tests provide critical information on how a patient's body is responding to cancer treatments such as chemotherapy or immunotherapy. They help assess the levels of various blood components, such as white blood cells, red blood cells, platelets, electrolytes, and liver and kidney function indicators. Monitoring these values can alert healthcare providers to potential side effects or complications from treatment. For instance, low white blood cell counts can indicate an increased risk for infections, while alterations in liver enzymes might point to liver toxicity from certain medications. Additionally, monitoring the tumor markers found in blood tests can help determine whether the cancer is responding to treatment or if there is a need to adjust the therapeutic approach. Regular assessments through blood tests are thus a vital part of comprehensive care for cancer patients, enabling timely interventions to ensure safety and optimize treatment outcomes.

**10. What role does hydration play in chemotherapy treatment?**

- A. Prevents hair loss**
- B. Aids in drug elimination and reduces side effects**
- C. Improves the taste of food**
- D. Increases appetite**

Hydration plays a crucial role in chemotherapy treatment by aiding in drug elimination and reducing side effects. When patients are well-hydrated, the kidneys can function optimally to filter and eliminate the metabolites and waste products of chemotherapy drugs more efficiently. This promotes the excretion of potentially harmful substances from the body, which can help mitigate toxicities associated with chemotherapy, such as nephrotoxicity and electrolyte imbalances. Furthermore, adequate hydration can help alleviate some common side effects of chemotherapy, such as nausea and constipation. By ensuring that the body is sufficiently hydrated, patients may also experience less discomfort and other adverse reactions, contributing to an overall improvement in their quality of life during treatment. While hydration may not be directly related to hair loss, appetite, or taste perception, its significance in enhancing the overall efficacy and safety of chemotherapy cannot be overstated. Therefore, the option that describes hydration's role in aiding drug elimination and reducing side effects aligns precisely with its physiological functions during chemotherapy.